Valion Bio, Inc.
VBIONasdaq
$0.51
↑ +3.4%Jul 17 close · end-of-day
Price
1Y↓ -87.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$8.9M
Free Cash Flow (TTM)
-$7.0M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-80.3%
ROIC
-162.2%
Debt / Equity
—
Net Cash
$7.2M
Return 1Y
-87.6%
Company profile
Tivic Health Systems Inc. operates as a bioelectronic device company that delivers non-invasive neuromodulation products for the treatment of inflammatory conditions. Its primary product is ClearUP, a medical device intended to relieve sinus and nasal inflammation.
- CEO
- Jennifer Ernst
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 10
- Headquarters
- California
- Website
- tivichealth.com
Earnings
VBIO Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $1.3M | $1.8M | $1.2M | $780,000.00 | — |
| Gross profit | -$38,000.00 | $299,000.00 | $287,000.00 | $2,000.00 | — |
| Operating income | -$5.6M | -$10.1M | -$8.2M | -$4.5M | -$7.9M |
| Net income | -$8.5M | -$10.1M | -$8.2M | -$5.7M | -$8.9M |
| Diluted EPS | -$2.43 | -$104.32 | -$176.80 | -$19.68 | — |
| Operating cash flow | -$5.6M | -$8.9M | -$8.5M | -$5.7M | -$7.0M |
| Free cash flow | — | -$8.9M | -$8.6M | -$5.7M | -$7.0M |
| Gross margin | -3.0% | 16.3% | 24.4% | 0.3% | — |
| Operating margin | -448.1% | -548.8% | -701.1% | -573.8% | — |
| Net margin | -675.7% | -548.7% | -701.0% | -725.0% | — |
| Line item | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $126,000.00 | $180,000.00 | $70,000.00 | $86,000.00 | $146,000.00 | — | — | — |
| Gross profit | $44,000.00 | -$239,000.00 | $50,000.00 | $54,000.00 | -$145,000.00 | — | — | — |
| Operating income | -$1.4M | -$298,000.00 | -$1.4M | -$1.9M | -$2.5M | -$2.1M | — | -$5.6M |
| Net income | -$1.4M | -$1.5M | -$1.5M | -$1.9M | -$2.6M | -$2.8M | — | -$6.2M |
| Diluted EPS | -$0.23 | $3.07 | -$2.52 | -$2.19 | — | — | — | — |
| Operating cash flow | -$1.4M | -$1.4M | -$889,000.00 | -$1.8M | -$2.0M | -$2.3M | — | -$5.0M |
| Free cash flow | — | — | -$889,000.00 | -$1.8M | -$2.0M | -$2.3M | — | -$5.0M |
| Gross margin | 34.9% | -132.8% | 71.4% | 62.8% | -99.3% | — | — | — |
| Operating margin | -1135.7% | -165.6% | -1967.1% | -2248.8% | -1700.7% | — | — | — |
| Net margin | -1135.7% | -820.6% | -2145.7% | -2245.3% | -1778.1% | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.